Breaking News Instant updates and real-time market news.

SYRS

Syros Pharmaceuticals

$6.82

-0.575 (-7.78%)

05:05
04/10/19
04/10
05:05
04/10/19
05:05

Syros Pharmaceuticals price target lowered to $24 from $28 at Piper Jaffray

Piper Jaffray analyst Edward Tenthoff lowered his price target for Syros Pharmaceuticals to $24 from $28 to account for dilution of the company's recent $70M capital raise. The analyst, however, reiterates an Overweight rating on the name. Syros is developing potentially best-in-class CDK7 inhibitors, Tenthoff tells investors in a research note. He points out that data from the expansion cohorts in ovarian cancer are expected in Q4.

  • 07

    May

SYRS Syros Pharmaceuticals
$6.82

-0.575 (-7.78%)

11/16/18
PIPR
11/16/18
NO CHANGE
Target $28
PIPR
Overweight
Syros Phase I dose escalation data 'encouraging,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff found the Phase I dose escalation data presented by Syros Pharmaceuticals for its CDK7 inhibitor SY-1365 "encouraging." Intravenous SY-1365 was safe and well tolerated with manageable adverse events, Tenthoff tells investors in a research note. The analyst points out that one relapsed ovarian cancer patient achieved partial response with six additional patients with stable disease, bringing the disease control rate to 37% in seven of 19 evaluable patients. He reiterates an Overweight rating on Syros with a $28 price target.
02/14/19
OPCO
02/14/19
INITIATION
Target $13
OPCO
Outperform
Syros Pharmaceuticals assumed with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach assumed coverage of Syros Pharmaceuticals with an Outperform rating and a $13 price target. The analyst believes the company's lead program, SY-1425, has demonstrated compelling clinical proof-of-concept in a biomarker-defined population of acute myeloid leukemia patients and has an opportunity for approval in multiple therapeutic settings. However, recent changes in the AML competitive landscape, such as the approval of venetoclax, could limit uptake and prolong development timelines relative to previous estimates, he contends. Nonetheless, Breidenbach sees SY-1425 + azacitidine as a promising combination therapy in AML and expects the company to announce updated development plans in early 2019.
03/08/19
JMPS
03/08/19
INITIATION
Target $18
JMPS
Outperform
Syros Pharmaceuticals initiated with an Outperform at JMP Securities
JMP Securities transferred coverage of Syros Pharmaceuticals to analyst Jason Butler, who established an Outperform rating and $18 price target on the stock. He believes the company's recently updated clinical development strategies can provide faster paths to market and maximize commercial potential for SY-1425 and SY-1365, Butler tells investors.
03/08/19
03/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tilray (TLRY) initiated with an Underperform at Jefferies. 2. BB&T (BBT) initiated with a Buy at Odeon Capital. 3. Syros Pharmaceuticals (SYRS) initiated with an Outperform at JMP Securities. 4. W&T Offshore (WTI) initiated with a Buy at Stifel. 5. Ichor Holdings (ICHR) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

BWEN

Broadwind Energy

$2.17

0.02 (0.93%)

07:18
06/17/19
06/17
07:18
06/17/19
07:18
Hot Stocks
Broadwind Energy announces $29M of new tower orders »

Broadwind Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$8.24

-0.37 (-4.30%)

07:17
06/17/19
06/17
07:17
06/17/19
07:17
Recommendations
Teva analyst commentary  »

Citi removes Teva from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REVG

REV Group

$12.99

-0.555 (-4.10%)

07:17
06/17/19
06/17
07:17
06/17/19
07:17
Recommendations
REV Group analyst commentary  »

REV Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIXX

Homology Medicines

$18.56

0.16 (0.87%)

07:16
06/17/19
06/17
07:16
06/17/19
07:16
Hot Stocks
Homology Medicines says single dose HMI-102 resulted in long-term PKU correction »

Homology Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNV

Synovus

$33.01

0.08 (0.24%)

07:15
06/17/19
06/17
07:15
06/17/19
07:15
Conference/Events
Synovus management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

ARRY

Array BioPharma

$29.59

0.17 (0.58%)

, PFE

Pfizer

$42.75

0.24 (0.56%)

07:14
06/17/19
06/17
07:14
06/17/19
07:14
Hot Stocks
Breaking Hot Stocks news story on Array BioPharma, Pfizer »

Array BioPharma up 59% to…

ARRY

Array BioPharma

$29.59

0.17 (0.58%)

PFE

Pfizer

$42.75

0.24 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 16

    Sep

ALNY

Alnylam

$70.04

-1.15 (-1.62%)

07:14
06/17/19
06/17
07:14
06/17/19
07:14
Hot Stocks
Alnylam announces lumasiran results, full patient enrollment in ILLUMINATE-A, »

Alnylam announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOLD

Amicus

$11.35

-0.31 (-2.66%)

07:13
06/17/19
06/17
07:13
06/17/19
07:13
Initiation
Amicus initiated  »

Amicus initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 16

    Sep

PLX

Protalix

$0.42

-0.017 (-3.89%)

07:13
06/17/19
06/17
07:13
06/17/19
07:13
Hot Stocks
Protalix completes enrollment in Phase III Bright clinical trial of PRX-102 »

Protalix BioTherapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROP

Roper Technologies

$364.63

-0.43 (-0.12%)

07:12
06/17/19
06/17
07:12
06/17/19
07:12
Conference/Events
Roper Technologies management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

RTLR

Rattler Midstream

$19.21

-0.195 (-1.01%)

07:12
06/17/19
06/17
07:12
06/17/19
07:12
Initiation
Rattler Midstream initiated  »

Rattler Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RWLK

ReWalk Robotics

$5.21

-0.215 (-3.97%)

07:11
06/17/19
06/17
07:11
06/17/19
07:11
Upgrade
ReWalk Robotics rating change  »

ReWalk Robotics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORGS

Orgenesis

$4.21

-0.09 (-2.09%)

07:11
06/17/19
06/17
07:11
06/17/19
07:11
Hot Stocks
Orgenesis gets Orphan Drug designation for Autologous Insulin Producing cells »

Orgenesis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBMG

Cellular Biomedicine

$14.68

-0.62 (-4.05%)

07:09
06/17/19
06/17
07:09
06/17/19
07:09
Hot Stocks
Cellular Biomedicine: First patient dosed in Phase 1 trial of anti-CD20 CAR-T »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USAP

Universal Stainless & Alloy

$14.10

0.06 (0.43%)

07:08
06/17/19
06/17
07:08
06/17/19
07:08
Hot Stocks
Universal Stainless & Alloy reports fire at North Jackson, Ohio facility »

Universal Stainless &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$8.24

-0.37 (-4.30%)

07:08
06/17/19
06/17
07:08
06/17/19
07:08
Recommendations
Teva analyst commentary  »

Teva price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$117.48

-7.52 (-6.02%)

, CELG

Celgene

$96.49

0.07 (0.07%)

07:06
06/17/19
06/17
07:06
06/17/19
07:06
Hot Stocks
BeiGene, Celgene to terminate global collaboration for tislelizumab »

BeiGene (BGNE) announced…

BGNE

BeiGene

$117.48

-7.52 (-6.02%)

CELG

Celgene

$96.49

0.07 (0.07%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 27

    Jun

  • 25

    Jul

  • 03

    Sep

  • 16

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

TWIN

Twin Disc

$14.02

0.125 (0.90%)

07:06
06/17/19
06/17
07:06
06/17/19
07:06
Hot Stocks
Twin Disc names James Feiertag as president and COO, effective May 1 »

Twin Disc has appointed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTLR

Rattler Midstream

$19.21

-0.195 (-1.01%)

, FANG

Diamondback Energy

$98.98

-1.15 (-1.15%)

07:06
06/17/19
06/17
07:06
06/17/19
07:06
Initiation
Rattler Midstream, Diamondback Energy initiated  »

Rattler Midstream…

RTLR

Rattler Midstream

$19.21

-0.195 (-1.01%)

FANG

Diamondback Energy

$98.98

-1.15 (-1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 13

    Sep

TYPE

Monotype Imaging

$16.33

0.01 (0.06%)

07:06
06/17/19
06/17
07:06
06/17/19
07:06
Hot Stocks
Monotype Imaging CFO Anthony Callini to step down »

Monotype Imaging…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTLR

Rattler Midstream

$19.21

-0.195 (-1.01%)

07:06
06/17/19
06/17
07:06
06/17/19
07:06
Initiation
Rattler Midstream initiated  »

Rattler Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:05
06/17/19
06/17
07:05
06/17/19
07:05
General news
FX Update: Trading has been directionally unambitious »

FX Update: Trading has…

CASI

Casi Pharmaceuticals

$3.13

-0.05 (-1.57%)

07:04
06/17/19
06/17
07:04
06/17/19
07:04
Hot Stocks
Casi Pharmaceuticals acquires rights to commercialize anti-CD19 T-cell therapy »

CASI Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

IDYA

Ideaya Biosciences

$10.70

-0.1 (-0.93%)

07:04
06/17/19
06/17
07:04
06/17/19
07:04
Initiation
Ideaya Biosciences initiated  »

Ideaya Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SF

Stifel Financial

$56.60

-0.82 (-1.43%)

07:04
06/17/19
06/17
07:04
06/17/19
07:04
Hot Stocks
Stifel Financial to acquire capital markets business of GMP Capital »

Stifel Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.